1986•PubMedRequires access

Clavulanic acid, a novel beta-lactamase inhibitor--a case study in drug discovery and development.

ALLAN G. BROWN

Abstract

The research programme leading to the discovery of clavulanic acid and the olivanic acids (carbapenems) is reviewed. The beta-lactamase inhibitory properties of clavulanic acid and its development as a formulation with amoxycillin (Augmentina) and ticarcillin (Timentin) are described. The chemistry of clavulanic acid as well as the properties of the carbapenem family of antibiotics is outlined as are the other beta-lactamase inhibitors prompted by the development of clavulanic acid.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 29 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Clavulanic acid, Beta-Lactamase Inhibitors, Ticarcillin, Beta-lactamase, Antibiotics, Drug discovery, Microbiology, Chemistry